avalglucosidase alfa
Selected indexed studies
- Avalglucosidase alfa: First Approval. (Drugs, 2021) [PMID:34591286]
- Avalglucosidase Alfa. (, 2006) [PMID:34406724]
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. (Lancet Neurol, 2021) [PMID:34800399]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. (2021) pubmed
- Avalglucosidase alfa: First Approval. (2021) pubmed
- Avalglucosidase Alfa. (2006) pubmed
- PMID:40504966 (2022) pubmed
- PMID:38696631 (2022) pubmed
- Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. (2023) pubmed
- Avalglucosidase Alfa-ngpt. (2021) pubmed
- Evaluating avalglucosidase alfa for the management of late-onset Pompe disease. (2024) pubmed
- Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. (2023) pubmed
- Regulatory news: Avalglucosidase alfa-ngpt (Nexviazyme) for late-onset Pompe disease-FDA approval summary. (2022) pubmed